Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage. Zura Bio is headquartered in San Diego, CA with team members in the UK and USA.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $80M
Founded date: 2022
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 06.06.2023 | - | $80M | - | socaltech.... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 06.06.2023 | Zura Bio Completes Approximately $80M Financing | Zura Bio (Nasdaq: “ZURA”), a San Diego, CA-based multi-asset clinical-stage biotechnology company, r... | finsmes.co... |
| 27.04.2023 | Zura Bio Gets $80M In PIPE | San Diego-based biotechnology developer Zura Bio, a publicly traded biotech company focused on devel... | socaltech.... |